Lineage Cell Therapeutics Inc. Registered Shares o.N.

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

24.49%

Market Cap

-

P/E Ratio

0.00

Dividend Yield

0.00 %

Earnings per Share

-0.24 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE0.947 G0 Units
PRICE DETERMINATION TIME07/23/2026 / 09:56:25 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW0.9820.938
PREV. DAY'S PRICE0.971 (07/22)
CHANGE DAY BEFORE
-0.02
-2.47 %
52 WEEK HIGH / LOW1.66 (03/02)0.72 (08/11)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
-0.12-0.09-0.24-0.05-0.10
DIVIDENDS PER SHARE
0.000.000.00--
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
-----
PRICE - BOOK RATIO
3.011.419.11--
PRICE - SALES RATIO
21.0410.5926.40--
PRICE - CASH FLOW RATIO
-----
Further Key Figures

Master Data

WKN
A2PP89
ISIN
US53566P1093
SYMBOL
BT3
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
LINEAGE CELL THERAP.
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
-
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
-
MARKET CAPITALISATION
-

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-8.57 %
-10.09 %
-29.12 %
-31.13 %
24.49 %
-24.73 %
-56.26 %
-26.99 %
HIGH1.061.191.391.661.661.662.441.66
LOW0.940.940.940.940.720.320.320.94

Dividende

pro Aktie
LINEAGE CELL THERAP. does not deliver dividend information

Company profile

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.